Genetic study of orosomucoid by isoelectric focusing and immunoprinting in patients with carcinoma.
The carbohydrate moiety of the orosomucoid (ORM) molecule shows microheterogeneity [1] and the pteridine-containing variant seems to be tumor-specific [2-4]. However, there also exists a genetic (protein-related) polymorphism coded by the ORM1 and ORM2 loci on chromosome 9 [5, 6]. To investigate the relationship between ORM1 gene products and the development of carcinoma, we analyzed the ORM1 phenotypes of desialated sera from 125 patients with carcinoma. The allele frequencies were estimated for ORM1*F1 0.556, ORM1*F2 0.012 and ORM1*S 0.432. In comparison to healthy individuals from the same geographical area [6] the ORM1 S phenotypes are significantly more frequent in carcinoma patients. The patients' sera frequently showed additional ORM-positive proteins which focused slightly cathodically to the ORM 2 A band. These proteins may represent posttranslational modifications of the ORM1*S allele product. Whether these modifications are tumor-specific and related to the carbohydrate moiety of the molecule must be confirmed in further studies.
Mittermüller
J
J
GSF Forschungszentrum für Umwelt und Gesundheit, Institut für Klinische Hämatologie, München, Germany.
Weidinger
S
S
D000483:Alleles; D000906:Antibodies; D005260:Female; D005787:Gene Frequency; D006801:Humans; D007525:Isoelectric Focusing; D008297:Male; D009369:Neoplasms / Q000737:chemistry* / Q000235:genetics*; D009961:Orosomucoid / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification*; D010641:Phenotype; D011110:Polymorphism, Genetic
D000906:Antibodies; D009961:Orosomucoid